Adjuvant Radiation Boosts High-Risk Bladder Cancer Control
Adjuvant radiotherapy significantly reduces the risk of locoregional recurrence in patients with high-risk muscle-invasive bladder cancer. A study showed that patients receiving radiotherapy had better outcomes in disease-free and overall survival compared to those under observation. The findings suggest that incorporating adjuvant pelvic IMRT into standard treatment may enhance patient care with minimal added toxicity.
- ▪Adjuvant radiotherapy cut locoregional recurrence risk by more than half among patients undergoing radical cystectomy for high-risk muscle-invasive bladder cancer.
- ▪At 2 years, locoregional recurrence-free survival was 87.1% with radiotherapy compared to 76.0% with observation.
- ▪Serious adverse events were uncommon, with only 1.6% of radiotherapy patients experiencing severe toxicity.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Among patients undergoing radical cystectomy and perioperative chemotherapy for high-risk muscle-invasive bladder cancer (MIBC), adjuvant radiotherapy cut locoregional recurrence risk by more than half — with numeric improvements in disease-free and overall survival.METHODOLOGY:Locally advanced MIBC is treated with neoadjuvant chemotherapy followed by radical cystectomy and pelvic nodal dissection, yet about half of patients have disease recurrence within 3 years. Adjuvant radiotherapy can improve pelvic disease control and, with modern intensity-modulated radiotherapy (IMRT) planning, may do so more safely.Researchers conducted a phase 3 randomized controlled trial across four academic centers in India, enrolling 153 patients with nonmetastatic MIBC at high risk after radical…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
